Highlights the need for a pathogenetic classification to optimize the timing and selection of therapies for post-infarct no-reflow.
Supports pathogenetic classification for post-infarct no-reflow to guide therapy timing; leaves open prospective validation before adoption.
therapeutic approach comprises drugs with multiple actions on the microvascular damage produced by ischaemia/reperfusion, as well as knowledge of the time course of events in order to optimise the timing of administration . . . . . . . . .
No takes yet. Share an insight, caveat, or question.
Leda Galiuto (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: